Schonfeld Strategic Advisors’s LENZ Therapeutics LENZ Stock Holding History

Schonfeld Strategic Advisors’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Buy	53,462 +14,177	+36%	+$114K	﹤0.01%	2029
2026 Q1	$359K	Buy	+39,285	New	+$552K	﹤0.01%	1507
2024 Q4	–	Sell	-107,300	Closed	-$2.55M	–	2466
2024 Q3	$2.55M	Buy	+107,300	New	+$2.38M	0.02%	784
2022 Q4	–	Sell	-3,371	Closed	-$75K	–	3073
2022 Q3	$75K	Sell	3,371 -2,986	-47%	-$71.2K	﹤0.01%	2598
2022 Q2	$122K	Buy	+6,357	New	+$142K	﹤0.01%	2079

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

7IH

72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Schonfeld Strategic Advisors's LENZ Position: Q2 2026 in Review

Schonfeld Strategic Advisors increased its LENZ Therapeutics (LENZ) stake by 36% in Q2 2026, buying an estimated $114K and bringing the position to 53,462 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Schonfeld Strategic Advisors first reported a position in LENZ in Q2 2022 and has held it in 5 quarters since. The position peaked at $2.55M in Q3 2024. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

Schonfeld Strategic Advisors held 53,462 shares of LENZ Therapeutics worth $304K as of Q2 2026.
Schonfeld Strategic Advisors bought 14,177 LENZ Therapeutics shares in Q2 2026, an estimated $114K.
LENZ Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2029 holding.
Schonfeld Strategic Advisors first reported a position in LENZ Therapeutics in Q2 2022 and has held it in 5 quarters since.
Schonfeld Strategic Advisors's LENZ Therapeutics position peaked at $2.55M in Q3 2024.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.